PE38797A1 - Formulaciones de analogos monomeros de insulina - Google Patents

Formulaciones de analogos monomeros de insulina

Info

Publication number
PE38797A1
PE38797A1 PE1996000217A PE00021796A PE38797A1 PE 38797 A1 PE38797 A1 PE 38797A1 PE 1996000217 A PE1996000217 A PE 1996000217A PE 00021796 A PE00021796 A PE 00021796A PE 38797 A1 PE38797 A1 PE 38797A1
Authority
PE
Peru
Prior art keywords
insulin
analog
nacl
monomer
crystal
Prior art date
Application number
PE1996000217A
Other languages
English (en)
Inventor
Felippis Michael Rosario De
Bruce Hill Frank
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE38797A1 publication Critical patent/PE38797A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

SE REFIERE UNA COMPOSICION PARA VIA PARENTERAL, QUE COMPRENDE: 1) 100 U/ml O 40 U/ml DE UNA SUSPENSION ACUOSA ESTERIL DE UN ANALOGO MONOMERO DE INSULINA (70% CRISTAL + 30% AMORFO); 2) 7 mg/ml DE NaCl; 3) 1,6 mg/ml DE AcNa; 4) DE 0,04 mg/ml A 20 mg/ml DE Zn+; 4) CONSERVANTE; A UN pH DE 7,0 A 7,4; TAL QUE MENOS DE 5% DEL ANALOGO PRESENTE EN LA SUSPENSION ESTA EN ESTADO DISUELTO. TAMBIEN SE REFIERE AL CRISTAL DEL ANALOGO DE INSULINA Y SU PREPARACION POR PRECIPITACION QUE COMPRENDE COMBINAR DOS SOLUCIONES (A) Y (B), EN DONDE (A) ES LA SECCION INSULINA, QUE COMPRENDE: a) DE 300 U/ml A 2 000 U/ml DEL ANALOGO DE INSULINA, b) FENOL Y c) Zn+, A UN pH DE 2 A 3; Y (B) ES LA SECCION TAMPON, QUE COMPRENDE: d) DE 130 mg/ml A 270 mg/ml DE NaCl, Y e) DE 5,0 mg/ml A 55,0 mg/ml DEL TAMPON, A UN pH DE 10,5 A 12,0; OBTENIENDOSE LA SOLUCION QUE COMPRENDE: i) DE 200 A 1 200 U/ml DE LA INSULINA, ii) DE 50 mg/ml A 100 mg/ml DE NaCl, iii) DE 2mg/ml A 20 mg/ml DEL TAMPON, iv) EXCESO DE (c), Y OPCIONALMENTE, v) DE 500ppm A 3 000ppm DE (b). EL ANALOGO MONOMERO DE INSULINA ES INSULINA HUMANA LYSB28-PROB29, QUE ES MENOS PROPENSO A DIMERIZARSE O AUTOASOCIARSE COMO LA INSULINA HUMANA Y FORMA CRISTALES ESTABLES DE EFECTO PROLONGADO
PE1996000217A 1995-03-31 1996-03-28 Formulaciones de analogos monomeros de insulina PE38797A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41488095A 1995-03-31 1995-03-31

Publications (1)

Publication Number Publication Date
PE38797A1 true PE38797A1 (es) 1997-10-04

Family

ID=23643384

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000217A PE38797A1 (es) 1995-03-31 1996-03-28 Formulaciones de analogos monomeros de insulina

Country Status (23)

Country Link
US (1) US5952297A (es)
EP (1) EP0735048A1 (es)
JP (1) JPH11502856A (es)
KR (1) KR19980703425A (es)
CN (1) CN1185114A (es)
AR (1) AR002976A1 (es)
AU (1) AU720300B2 (es)
BR (1) BR9607935A (es)
CA (1) CA2216516A1 (es)
CO (1) CO4700482A1 (es)
CZ (1) CZ305297A3 (es)
EA (1) EA000970B1 (es)
HU (1) HUP9801700A3 (es)
IL (1) IL117696A (es)
MX (1) MX9707428A (es)
NO (1) NO974498L (es)
NZ (1) NZ305719A (es)
PE (1) PE38797A1 (es)
PL (1) PL322626A1 (es)
TR (1) TR199701078T1 (es)
WO (1) WO1996030040A1 (es)
YU (1) YU18596A (es)
ZA (1) ZA962502B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE79099A1 (es) * 1997-06-13 1999-08-24 Lilly Co Eli Formulaciones de insulina estables
SI0884053T1 (en) * 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
US20010053761A1 (en) * 1998-01-08 2001-12-20 Dimarchi Richard Dennis Method for administering aspb28-human insulin
AU2827199A (en) * 1998-03-24 1999-10-18 Klavs Holger Jorgensen Novel preparation of protracted acting human insulin
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
CN1125081C (zh) 1999-09-08 2003-10-22 中国科学院上海生物化学研究所 重组天然和新型人胰岛素及其制备方法
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
WO2002051428A1 (fr) * 2000-12-25 2002-07-04 Shiseido Company, Ltd. Composition de parfum stimulant le systeme sympathique
ES2278020T3 (es) * 2001-02-09 2007-08-01 Genentech, Inc. Cristalizacion de igf-1.
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7683029B2 (en) * 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
RU2393168C2 (ru) 2004-07-19 2010-06-27 Биокон Лимитед Инсулин-олигомерные конъюгаты, их препараты и применения
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
EP2203181B1 (en) 2007-10-16 2018-02-14 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
MY152979A (en) 2008-01-09 2014-12-15 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
WO2010028175A1 (en) 2008-09-08 2010-03-11 The Board Of Trustees Of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
JP5508438B2 (ja) 2009-01-28 2014-05-28 スマートセルズ・インコーポレイテツド 制御された薬物送達のための複合体に基づくシステム
CA2750252A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
CN102316892B (zh) 2009-02-12 2014-06-04 西马生物医学计划公司 心肌营养素-1用于治疗代谢病的用途
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
JP5670421B2 (ja) 2009-03-31 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング コンポーネント表面のコーティング方法
EP2432531B1 (de) 2009-05-18 2019-03-06 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
TWI468171B (zh) 2009-11-13 2015-01-11 Sanofi Aventis Deutschland 含ｇｌｐ－１激動劑及甲硫胺酸之醫藥組成物
ES2855146T3 (es) 2009-11-13 2021-09-23 Sanofi Aventis Deutschland Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
MX2012005961A (es) 2009-11-25 2012-06-14 Boehringer Ingelheim Int Nebulizador.
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
EP2694220B1 (de) 2011-04-01 2020-05-06 Boehringer Ingelheim International GmbH Medizinisches gerät mit behälter
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
RU2019133674A (ru) 2013-04-03 2020-05-20 Санофи Лечение сахарного диабета с помощью составов инсулинов длительного действия
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
EP3077414B1 (en) 2013-12-04 2020-06-17 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin
SI3928818T1 (sl) 2014-05-07 2023-04-28 Boehringer Ingelheim International Gmbh Razpršilnik in vsebnik
DK3139979T3 (da) 2014-05-07 2023-10-09 Boehringer Ingelheim Int Enhed, forstøver og fremgangsmåde
ES2874029T3 (es) 2014-05-07 2021-11-04 Boehringer Ingelheim Int Nebulizador
BR112017000175B1 (pt) * 2014-07-08 2023-11-21 Amphastar Pharmaceuticals,Inc. Método de preparação de uma insulina inalável adequada para a liberação pulmonar e partículas de insulina micronizadas
WO2016032869A1 (en) 2014-08-26 2016-03-03 Merck Sharp & Dohme Corp. Method for preparing crystalline insulin or insulin analog compositions
CR20170314A (es) 2014-12-12 2017-10-20 Sanofi Aventis Deutschland Formulación de relación fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10322168B2 (en) 2016-01-07 2019-06-18 Amphastar Pharmaceuticals, Inc. High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
WO2021202802A1 (en) 2020-03-31 2021-10-07 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
EP4247429A1 (en) 2020-11-19 2023-09-27 Protomer Technologies Inc. Aromatic boron-containing compounds and insulin analogs
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2626228A (en) * 1945-05-17 1953-01-20 Novo Terapeutisk Labor As Method of producing crystalline insulin
US2882202A (en) * 1950-04-05 1959-04-14 Novo Terapeutisk Labor As Insulin crystal preparations and methods of producing them
US2648622A (en) * 1950-11-29 1953-08-11 Research Corp Purifying insulin by seeding with unclumped fibrils of insulin
US2882203A (en) * 1951-06-26 1959-04-14 Novo Terapeutisk Labor As Injectable insulin preparation with protracted effect
DK78069C (da) * 1952-06-23 1954-09-06 Novo Terapeutisk Labor As Fremgangsmåde til fremstilling af krystallinsk insulin.
US2849370A (en) * 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US2819999A (en) * 1953-11-13 1958-01-14 Novo Terapeutisk Labor As Process for crystallization of insulin using freeze dried insulin as seeding material
US2799622A (en) * 1953-11-14 1957-07-16 Novo Terapeutisk Labor As Process of producing insulin crystals of substantially uniform size and compositions thereof
US3060093A (en) * 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
AT304760B (de) * 1969-08-08 1973-01-25 Novo Terapeutisk Labor As Verfahren zur Reinigung von Insulin
DE2933946A1 (de) * 1979-08-22 1981-03-12 Hoechst Ag, 6000 Frankfurt Insulinkristallsuspension und verfahren zu ihrer herstellung.
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
AU711428B2 (en) * 1994-06-16 1999-10-14 Eli Lilly And Company Monomeric insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations

Also Published As

Publication number Publication date
CN1185114A (zh) 1998-06-17
AR002976A1 (es) 1998-05-27
IL117696A (en) 2000-01-31
JPH11502856A (ja) 1999-03-09
EA199700285A1 (ru) 1998-02-26
ZA962502B (en) 1997-09-29
EA000970B1 (ru) 2000-08-28
IL117696A0 (en) 1996-07-23
KR19980703425A (ko) 1998-11-05
NO974498L (no) 1997-10-08
US5952297A (en) 1999-09-14
HUP9801700A3 (en) 1998-12-28
PL322626A1 (en) 1998-02-02
YU18596A (sh) 1998-07-10
CO4700482A1 (es) 1998-12-29
NZ305719A (en) 1998-09-24
HUP9801700A2 (hu) 1998-11-30
AU720300B2 (en) 2000-05-25
BR9607935A (pt) 1998-06-02
AU5381296A (en) 1996-10-16
WO1996030040A1 (en) 1996-10-03
MX9707428A (es) 1997-12-31
CZ305297A3 (cs) 1998-02-18
CA2216516A1 (en) 1996-10-03
EP0735048A1 (en) 1996-10-02
TR199701078T1 (xx) 1998-01-21
NO974498D0 (no) 1997-09-29

Similar Documents

Publication Publication Date Title
PE38797A1 (es) Formulaciones de analogos monomeros de insulina
US4725586A (en) Surgical solution
AT402259B (de) Verfahren zur herstellung eines stabilen pharmazeutischen präparats mit einem gehalt an granulozytkolonie stimulierendem faktor
CA2019466C (en) Minerals in bioavailable form
US6605295B1 (en) Storage-stable ophthalmic compositions comprising diclofenac and ofloxacin
DE3837825A1 (de) Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
PL1755630T3 (pl) Kompozycje farmaceutyczne z brodaczki włosowatej i dziurawca oraz ich zastosowanie
RU2015119603A (ru) Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc
EP0414373B2 (en) Stable solution of hyaluronate in a balanced salt medium
Van Alphen Acetylcholine synthesis in corneal epithelium
JPH115744A (ja) ヒアルロン酸含有の外用水溶液製剤
KR920700627A (ko) 치료제로서 1-페닐-2-아미노에탄올 유도체의 신규한 용도
Fox et al. Cerium sulphadiazine as a topical agent for burn wound infections: a comparison with silver sulphadiazine and zinc sulphadiazine
EP0012272B1 (de) Protektive Lösung für Herz und Niere und Verfahren zu deren Herstellung
Boissevain et al. A note on the effect of synthetic ascorbic acid (vitamin C) on the growth of the tubercle bacillus
JPH0780760B2 (ja) 安定化されたフエニレフリン系液剤
JPH075456B2 (ja) 点眼液
JP2017019867A (ja) ヒアルロン酸含有水性製剤の増粘及び粘度低下抑制剤
DE10045343B4 (de) Verwendung einer wässrigen Lösung oder Suspension zum Heilen des Hornhautepithels
RU2683651C2 (ru) Лекарственное средство для лечения кератоконуса и других дегенеративных заболеваний роговицы и фармацевтические препараты на его основе
CN102215819B (zh) 具有相对低的离子强度的药物组合物
ES2229160T3 (es) Antiseptico para heridas y membranas mucosas.
RU2003113987A (ru) Способ лечения и профилактики заболеваний воздействием на биологически активные точки и зоны
Gillie Endemic goiter
KR900000746B1 (ko) 주사제용 세파만돌 나페이트 제제의 안정화 방법

Legal Events

Date Code Title Description
FC Refusal